Durvalumab Long-Term Safety and Efficacy Study - WAVE

Study identifier:D910FC00001

ClinicalTrials.gov identifier:NCT04078152

EudraCT identifier:2019-001402-20

CTIS identifier:N/A

Recruitment Complete

Official Title

An Open-Label, Multi-Center, Global Study to Evaluate Long Term Safety and Efficacy in Patients Who are Receiving or Who Previously Received Durvalumab in Other Protocols (WAVE)

Medical condition

solid tumor

Phase

Phase 4

Healthy volunteers

No

Study drug

Durvalumab

Sex

All

Actual Enrollment

163

Study type

Interventional

Age

18 Years - 130 Years

Date

Study Start Date: 05 Sept 2019
Primary Completion Date: 31 Oct 2022
Estimated Study Completion Date: 30 Sept 2024

Study design

Allocation: Non-randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Aug 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

IQVIA, PAREXEL, Medidata, CISCRP

Inclusion and exclusion criteria